CDC Website CDC Website

To Join the NPIN community or

Home » Martin Delaney Collaboratory for Pediatric HIV Cure Research (UM1 Clinical Trial Not Allowed)

COVID-19 Information |

For COVID-19 testing information please visit:

Directly contact organizations to find out about changes to services or hours.

Martin Delaney Collaboratory for Pediatric HIV Cure Research (UM1 Clinical Trial Not Allowed)

Funding Opportunity Announcement (FOA) is soliciting applications to support research on HIV cure in pediatric populations. This FOA will support coordinated basic, clinical, and applied research focused on developing strategies to achieve an HIV cure, defined as either sustained viral remission or eradication of HIV infection. The cure of HIV infection in people living with HIV (PLWH) is one of the highest priorities of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The goal of the Martin Delaney Collaboratory program is to accelerate progress towards developing strategies to achieve either eradication of HIV infection from the body or a sustained viral remission, as defined by sustained viral suppression following cessation of antiretroviral therapy. Funded projects under this FOA will be expected to expand the knowledge base on HIV latency and persistence in pediatric populations, design and evaluate innovative cure strategies, develop and evaluate assays and other modalities to accurately characterize HIV reservoirs and translate findings to the clinical settings. This funding opportunity will target perinatally infected children and adolescents up to 24 years of age with a primary focus on early treated children.

Letter of Intent Date
Application Due Date
Project Start Date
Application Contact
Branch Chief, Grants Management Officer/AIDS and CTU Division Coordinator
Technical Contact
Lombo, Ph.D.
Scientific/Research Contact
Fund Duration
The total project period must be 5 years.

Fund Number: 


Fund ID: 


Last modified: